Can-Fite BioPharma Files 6-K Report
Ticker: CANF · Form: 6-K · Filed: Nov 20, 2025 · CIK: 1536196
| Field | Detail |
|---|---|
| Company | Can-Fite Biopharma LTD. (CANF) |
| Form Type | 6-K |
| Filed Date | Nov 20, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, foreign-private-issuer, registration-statement
TL;DR
Can-Fite BioPharma filed a 6-K on Nov 20, 2025, incorporating a press release into its SEC filings.
AI Summary
On November 20, 2025, Can-Fite BioPharma Ltd. filed a Form 6-K, incorporating by reference a press release into its existing Registration Statements on Form S-8 and Form F-3. This filing is for the month of November 2025 and indicates the company is a foreign private issuer.
Why It Matters
This filing updates the SEC with information relevant to Can-Fite BioPharma's ongoing reporting obligations as a foreign private issuer, potentially impacting investors' access to timely information.
Risk Assessment
Risk Level: low — This is a routine filing for a foreign private issuer and does not appear to contain new material financial or operational information.
Key Players & Entities
- Can-Fite BioPharma Ltd. (company) — Filer of the 6-K report
- November 20, 2025 (date) — Date of filing and reporting period
- Form 6-K (document) — Type of SEC filing
- Form S-8 (document) — Registration statement incorporated by reference
- Form F-3 (document) — Registration statement incorporated by reference
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers that is furnished to the SEC to provide information that the issuer would be required to disclose to its security holders or make public in its home country.
What specific information is being incorporated by reference into Can-Fite BioPharma's registration statements?
The first paragraph of the press release attached as Exhibit 99.1 to this 6-K filing is incorporated by reference.
Which registration statements are being updated by this filing?
This filing updates Can-Fite BioPharma's Registration Statements on Form S-8 (File Nos. 333-227753, 333-271384 and 333-278525) and Form F-3 (File Nos. 333-236064, 333-274316, 333-262055, 333-276000 and 333-281872).
What is Can-Fite BioPharma Ltd.'s principal executive office address?
Can-Fite BioPharma Ltd.'s principal executive offices are located at 26 Ben Gurion Street, Ramat Gan 5257346, Israel.
Is Can-Fite BioPharma Ltd. required to file annual reports on Form 20-F or Form 40-F?
Can-Fite BioPharma Ltd. indicates it files annual reports under cover of Form 20-F.
Filing Stats: 266 words · 1 min read · ~1 pages · Grade level 10.5 · Accepted 2025-11-20 07:02:13
Filing Documents
- ea0266566-6k_canfite.htm (6-K) — 11KB
- ea026656601ex99-1_canfite.htm (EX-99.1) — 13KB
- ex99-1_001.jpg (GRAPHIC) — 8KB
- 0001213900-25-112837.txt ( ) — 37KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: November 20, 2025 By: /s/ Motti Farbstein Motti Farbstein Chief Executive Officer and Chief Financial Officer 3